Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

One clinical trial site activatedPatient enrollment expected in AprilTrial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin productAspire anticipates releasing initial clinical data from trial at the end of the second quarterAspire intends to request "fast track"…